Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, at least 18 years of age, with evidence of myocardial necrosis in a clinical setting consistent with a type I (spontaneous) acute myocardial infarction (AMI), in the last week.~Exclusion Criteria:~* Ongoing hemodynamic instability~* Evidence of hepatobiliary disease~* Evidence of chronic kidney disease (CKD) (Stage III, IV, or V), defined as moderate or severe renal impairment or if subject is receiving dialysis~* Evidence of unstable renal function~* History of acute kidney injury after previous exposure to an intravenous contrast agent.~* Known history of allergies, hypersensitivity or deficiencies to CSL112 or any of its components~* Other severe comorbid condition, concurrent medication, or other issue that renders the subject unsuitable for participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CSL112 - low dose (Type: EXPERIMENTAL): CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.
- CSL112 - high dose (Type: EXPERIMENTAL): CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).